Bruce Booth on LifeSciVC published a piece today that discusses where the new drugs are coming from. Highlighted in this analysis are 10 drug programs outlined in a recent Goldman Sachs report that are expected to have the highest near term commercial impact, and another 20 drugs that are considered to have high potential but are in earlier stages of clinical development. Booth points out that 76.7% of the 30 new drugs were either acquired by the current owners by in-licensing, or acquisition of either a Big Company or a smaller Biotech. That means only 7 were produced in-house. And of the top 10, 9 were acquired outside. Yes, 9 of 10.
This is just further indication that Big pharma companies that are unhappy with their current pipelines, have the money to still keep the engines chugging by acquiring the assets they need to keep putting out product. Although, we'll need to keep close watch to see how sustainable this model really is over time. It does seem clear though that while the money holds out, it is feasible to cherry pick the best candidates out there and still have something attractive at the end of the day to launch into the market.
Here's some more commentary on this story from Derek Lowe's In the Pipeline blog.
Posted by Bruce Lehr Mar 31st, 2014.